The application of brain-computer interface technologies poses context-specific challenges to trade secret protection.Throughout the entire lifecycle—from neural signal acquisition,algorithm training,and clinical validation to product operation—technical protocols,model parameters,clinical adaptation know-how,and other information flow through collaborative arrangements involving industry,academia,research institutions,and healthcare providers.Data sharing,external service provision,and personnel mobility may increase the risk of losing control over such information.In the context of brain-computer interfaces,the trade secret protection regime must recalibrate both the assessment of statutory requirements and the scope of protection.The secrecy requirement should be assessed through a differentiated analysis of raw neural activity,processed datasets,and competitively significant information.The commercial-value requirement should be substantively evaluated in light of research and development investment and the information's contribution to competitive advantage.The confidentiality measures requirement should be assessed contextually,taking account of both information control and collaborative practices.The scope and enforceability of protection should also be limited by personality rights and interests,personal information protection,medical ethics,and mandatory regulatory disclosure.Meanwhile,rules delimiting protectable subject matter should center on identifying the specific information claimed as secret.Confidentiality mechanisms for collaborative activities should be established,and judicial remedies should be strengthened through provenance review,contemporaneous process records,and mechanisms for tracing responsibility.These measures can protect competitive advantages generated through research and development while preventing trade secret protection from being improperly extended to facts about brain activity,information concerning the human body,or materials required for medical regulation.